Don't miss out on the latest news, evidence and CPD opportunities on medicines and medical tests - sign up today.
You have not selected any filters.
How would you advise a patient with well-controlled gastro-oesophageal reflux disease (GORD) who would like to continue their proton pump inhibitor (PPI) therapy?
Kyle, a 47-year-old man, presents with a history of low back pain for 8 days. He wants to know if he has damaged his back and is requesting imaging. What now?
How can you help patients put into practice non-pharmacological approaches to managing their knee osteoarthritis (OA)?
This series of six modules provides training for healthcare providers who conduct cervical screening tests and follow-up management for women aged 25–74. You can take the full course or choose any of the individual modules.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for people with diabetes and the largest contributor to the direct and indirect costs of diabetes. Approximately 65% of all CVD deaths in Australia occur in people with diabetes or prediabetes.Over the last few years, the management of type 2 diabetes has rapidly grown more complex. Recent developments include new medicines, emerging clinical trial results that provide cardiovascular (CV) outcome data related to blood glucose-lowering medicines, and an update to clinical guidelines. Now, more than ever, a clear, stepped approach is necessary to navigate the plethora of options available and reduce risk of microvascular and macrovascular complications.This webinar has been developed in partnership with the Australian Diabetes Society.This program is funded by Boehringer Ingelheim Pty Limited and Eli Lilly Australia Pty Limited and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.